Amalia Azzariti

List of Publications by Year
in descending order

135	3,468	94433	168389
papers	citations	37 h-index	53 g-index

142	142	142	6291
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The ERRÎ±â€“VDR axis promotes calcitriol degradation and estrogen signaling in breast cancer cells, while VDRâ€CYP24A1â€ERRÎ± overexpression correlates with poor prognosis in patients with basalâ€like breast cancer. Molecular Oncology, 2022, 16, 904-920.	4.6	10
2	Magnetic implants in vivo guiding sorafenib liver delivery by superparamagnetic solid lipid nanoparticles. Journal of Colloid and Interface Science, 2022, 608, 239-254.	9.4	17
3	Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. Molecular Cancer, 2022, 21, 20.	19.2	55
4	Microfluidic-Assisted Preparation of Targeted pH-Responsive Polymeric Micelles Improves Gemcitabine Effectiveness in PDAC: In Vitro Insights. Cancers, 2022, 14, 5.	3.7	12
5	BRAFV600E;K601Q metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy. Pharmacological Research, 2022, 182, 106323.	7.1	8
6	Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib. Biomedicine and Pharmacotherapy, 2021, 133, 111006.	5.6	16
7	The Interaction between Reactive Peritoneal Mesothelial Cells and Tumor Cells via Extracellular Vesicles Facilitates Colorectal Cancer Dissemination. Cancers, 2021, 13, 2505.	3.7	9
8	uPAR⁺ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients. , 2021, 9, e002372.		23
9	New Oxaliplatin-Pyrophosphato Analogs with Improved In Vitro Cytotoxicity. Molecules, 2021, 26, 3417.	3.8	4
10	Behind the Scene: Exploiting MC1R in Skin Cancer Risk and Prevention. Genes, 2021, 12, 1093.	2.4	15
11	The Pharmaceutical Technology Approach on Imaging Innovations from Italian Research. Pharmaceutics, 2021, 13, 1214.	4.5	4
12	Enhancing the biological activity of polyoxometalateâ€“peptide nano-fibrils by spacer design. RSC Advances, 2021, 11, 4952-4957.	3.6	21
13	Microfluidic preparation and in vitro evaluation of iRGD-functionalized solid lipid nanoparticles for targeted delivery of paclitaxel to tumor cells. International Journal of Pharmaceutics, 2021, 610, 121246.	5.2	23
14	Natural Bovine Coronavirus Infection in a Calf Persistently Infected with Bovine Viral Diarrhea Virus: Viral Shedding, Immunological Features and S Gene Variations. Animals, 2021, 11, 3350.	2.3	4
15	Salting-Out Approach Is Worthy of Comparison with Ultracentrifugation for Extracellular Vesicle Isolation from Tumor and Healthy Models. Biomolecules, 2021, 11, 1857.	4.0	2
16	Tomatine Displays Antitumor Potential in In Vitro Models of Metastatic Melanoma. International Journal of Molecular Sciences, 2020, 21, 5243.	4.1	18
17	The Role of Non-Coding RNAs as Prognostic Factor, Predictor of Drug Response or Resistance and Pharmacological Targets, in the Cutaneous Squamous Cell Carcinoma. Cancers, 2020, 12, 2552.	3.7	16
18	Hydroxy-Propil-Î²-Cyclodextrin Inclusion Complexes of two Biphenylnicotinamide Derivatives: Formulation and Anti-Proliferative Activity Evaluation in Pancreatic Cancer Cell Models. International Journal of Molecular Sciences, 2020, 21, 6545.	4.1	4

#	Article	IF	Citations
19	The Î²-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study. Scientific Reports, 2020, 10, 10465.	3.3	18
20	The Genetic Germline Background of Single and Multiple Primary Melanomas. Frontiers in Molecular Biosciences, 2020, 7, 555630.	3.5	6
21	Abstract 2238: Synergistic effect of sunitinib and PD-1 inhibitor nivolumab on colorectal cancerin vitroandin vivo. , 2020, , .		0
22	Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. Cancers, 2019, 11, 942.	3.7	66
23	Translational control mechanisms in cutaneous malignant melanoma: the role of eIF2Î±. Journal of Translational Medicine, 2019, 17, 20.	4.4	8
24	Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review. Cancers, 2019, 11, 539.	3.7	45
25	Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells. Scientific Reports, 2019, 9, 4099.	3.3	112
26	CAFs and TGF-Î² Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. Cancers, 2019, 11, 330.	3.7	71
27	Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma. Cancer Letters, 2019, 445, 1-10.	7.2	7
28	Dissecting the Potential Roles of Nigella sativa and Its Constituent Thymoquinone on the Prevention and on the Progression of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 16.	3.4	44
29	The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale). BMC Cancer, 2018, 18, 552.	2.6	14
30	Frizzled-10 and cancer progression: Is it a new prognostic marker?. Oncotarget, 2018, 9, 824-830.	1.8	16
31	Sorafenib delivery nanoplatform based on superparamagnetic iron oxide nanoparticles magnetically targets hepatocellular carcinoma. Nano Research, 2017, 10, 2431-2448.	10.4	54
32	Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers. International Journal of Pharmaceutics, 2017, 528, 485-497.	5.2	57
33	Potential therapeutic combination of beta-blockers and trabectedin in metastatic soft tissue sarcoma and ovarian cancer. Annals of Oncology, 2017, 28, vi66-vi67.	1.2	0
34	The HMGA1 Pseudogene 7 Induces miR-483 and miR-675 Upregulation by Activating Egr1 through a ceRNA Mechanism. Genes, 2017, 8, 330.	2.4	24
35	Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. International Journal of Molecular Sciences, 2017, 18, 418.	4.1	47
36	Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity. Oncotarget, 2017, 8, 50845-50863.	1.8	9

#	Article	IF	Citations
37	The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response. Oncotarget, 2016, 7, 25135-25149.	1.8	6
38	Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma. OncoTargets and Therapy, 2016, Volume 9, 4681-4686.	2.0	9
39	Synthesis, Characterization, and Cytotoxicity of the First Oxaliplatin Pt(IV) Derivative Having a TSPO Ligand in the Axial Position. International Journal of Molecular Sciences, 2016, 17, 1010.	4.1	19
40	Probing the interaction between cisplatin and the therapeutic monoclonal antibody trastuzumab. RSC Advances, 2016, 6, 29229-29236.	3.6	4
41	Expression of proteins involved in DNA damage response in familial and sporadic breast cancer patients. International Journal of Cancer, 2016, 138, 110-120.	5.1	13
42	Detrimental effects of melanocortinâ€1 receptor (<scp>MC</scp>1R) variants on the clinical outcomes of <scp>BRAF</scp> V600 metastatic melanoma patients treated with <scp>BRAF</scp> inhibitors. Pigment Cell and Melanoma Research, 2016, 29, 679-687.	3.3	8
43	New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 2710-2718.	4.1	27
44	Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin‐332/α3 integrin axis recovery of focal adhesion kinase ubiquitination. Hepatology, 2016, 64, 2103-2117.	7.3	80
45	Melanoma and immunotherapy bridge 2015. Journal of Translational Medicine, 2016, 14, 65.	4.4	12
46	Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. World Journal of Gastroenterology, 2016, 22, 6287.	3.3	8
47	Influence of melanocortin-1 receptor (MC1R) polymorphisms on clinical outcomes of patients with metastatic melanoma harboring the BRAF mutation and treated with BRAF inhibitors.. Journal of Clinical Oncology, 2016, 34, 9574-9574.	1.6	0
48	Sequential combination of low dose chemo-modulating Temozolomide and Fotemustine in metastatic melanoma: clinical and molecular evaluation. Annals of Oncology, 2015, 26, vi26.	1.2	0
49	Negative influence of Melanocortin-1 receptor (MC1R) polymorphisms on clinical outcomes of metastatic melanoma (MM) patients (pts) harboring BRAF mutation and treated with BRAF inhibitors (BRAFi). Annals of Oncology, 2015, 26, vi26.	1.2	0
50	Mast Cells (MCs) Infiltration Affects Pancreatic Cancer (PC) Response To Gemcitabine Based Chemotherapy: In Vitro New Insights. Annals of Oncology, 2015, 26, vi101.	1.2	0
51	MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?. Oncotarget, 2015, 6, 23323-23341.	1.8	65
52	Possible predictive role of the soluble cd40 ligand (scd40l) in metastatic pancreatic ductal adenocarcinoma (PDAC) patients (pts) treated with first line folfirinox or gemcitabine/nab-paclitaxel combination. Annals of Oncology, 2015, 26, vi99.	1.2	0
53	MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors. Expert Opinion on Therapeutic Targets, 2015, 19, 1027-1035.	3.4	27
54	Sporadic melanoma in South-Eastern Italy: the impact of melanocortin 1 receptor (MC1R) polymorphism analysis in low-risk people and report of three novel variants. Archives of Dermatological Research, 2015, 307, 495-503.	1.9	18

#	Article	IF	Citations
55	Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. Journal of Translational Medicine, 2015, 13, 26.	4.4	34
56	Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?. Cancer Chemotherapy and Pharmacology, 2015, 76, 433-438.	2.3	9
57	miRNAs for the Detection of MultiDrug Resistance: Overview and Perspectives. Molecules, 2014, 19, 5611-5623.	3.8	24
58	Editorial (Thematic Issue: Targeted Therapies in Upper Gastrointestinal Malignancies). Current Medicinal Chemistry, 2014, 21, 947-947.	2.4	0
59	Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation. PLoS ONE, 2014, 9, e112025.	2.5	15
60	Predictive factors to targeted treatment in gastrointestinal carcinomas. Cancer Biomarkers, 2014, 14, 151-162.	1.7	5
61	Irradiation-induced angiosarcoma and anti-angiogenic therapy: A therapeutic hope?. Experimental Cell Research, 2014, 321, 240-247.	2.6	21
62	Trimethoxybenzanilide-Based P-Glycoprotein Modulators: An Interesting Case of Lipophilicity Tuning by Intramolecular Hydrogen Bonding. Journal of Medicinal Chemistry, 2014, 57, 6403-6418.	6.4	23
63	844: A novel strategy for the treatment of Hodgkin lymphoma. European Journal of Cancer, 2014, 50, S205.	2.8	0
64	P74 LAMININ-5 INDUCES RESISTANCE TO SORAFENIB IN HCC PRECLINICAL MODELS. Journal of Hepatology, 2014, 60, S91.	3.7	0
65	Extracellular ADP prevents neuronal apoptosis via activation of cell antioxidant enzymes and protection of mitochondrial ANT-1. Biochimica Et Biophysica Acta - Bioenergetics, 2014, 1837, 1338-1349.	1.0	6
66	New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies. Current Medicinal Chemistry, 2014, 21, 1039-1049.	2.4	7
67	Target Therapies in Pancreatic Carcinoma. Current Medicinal Chemistry, 2014, 21, 948-965.	2.4	43
68	The EGFR Pathway Regulates BCRP Expression in NSCLC Cells: Role of Erlotinib. Current Drug Targets, 2014, 15, 1322-1330.	2.1	23
69	The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line. Molecular Cancer, 2013, 12, 47.	19.2	15
70	Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Molecular Oncology, 2013, 7, 308-322.	4.6	54
71	Sigmaâ€2 Receptor Agonists as Possible Antitumor Agents in Resistant Tumors: Hints for Collateral Sensitivity. ChemMedChem, 2013, 8, 2026-2035.	3.2	52
72	Coâ€expression of CD133⁺/CD44⁺ in human colon cancer and liver metastasis. Journal of Cellular Physiology, 2013, 228, 408-415.	4.1	45

#	Article	IF	Citations
73	1044 LYSOPHOSPHATIDIC ACID RECEPTOR 6 (LPA6) PROMOTES HEPATOCELLULAR CARCINOMA GROWTH AND PROGRESSION THROUGH ACTIVATION OF PIM-3 PROTO-ONCOGENE KINASE. Journal of Hepatology, 2013, 58, S429.	3.7	0
74	Antitumor Potential of Conjugable Valinomycins Bearing Hydroxyl Sites: In Vitro Studies. ACS Medicinal Chemistry Letters, 2013, 4, 1189-1192.	2.8	22
75	Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors. Current Pharmaceutical Design, 2013, 19, 918-926.	1.9	9
76	Carcinogenesis of Pancreatic Adenocarcinoma: Precursor Lesions. International Journal of Molecular Sciences, 2013, 14, 19731-19762.	4.1	59
77	Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey. PLoS ONE, 2013, 8, e74402.	2.5	56
78	Synthetic Lethality to Overcome Cancer Drug Resistance. Current Medicinal Chemistry, 2012, 19, 3858-3873.	2.4	18
79	275 SORAFENIB EFFECTIVENESS IS INHIBITED IN PRESENCE OF LAMININ-5 IN HCC CELLS. Journal of Hepatology, 2012, 56, S114.	3.7	1
80	Synthesis, Characterization and Biological Evaluation of Ureidofibrate-Like Derivatives Endowed with Peroxisome Proliferator-Activated Receptor Activity. Journal of Medicinal Chemistry, 2012, 55, 37-54.	6.4	46
81	Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. Expert Opinion on Therapeutic Targets, 2012, 16, S111-S117.	3.4	13
82	Tumor endothelial markers as a target in cancer. Expert Opinion on Therapeutic Targets, 2012, 16, 1215-1225.	3.4	28
83	PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma. International Journal of Cancer, 2012, 130, 2505-2513.	5.1	36
84	A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents. Toxicology in Vitro, 2011, 25, 222-230.	2.4	15
85	Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. British Journal of Cancer, 2011, 104, 769-780.	6.4	52
86	214 PI3K CLASS 1B CONTROLS THE CELL CYCLE CHECKPOINT AT THE G2/M PHASE PROMOTING CELL PROLIFERATION IN HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2011, 54, S90.	3.7	0
87	Targeting EGFR in bilio-pancreatic and liver carcinoma. Frontiers in Bioscience - Scholar, 2011, S3, 16-22.	2.1	7
88	The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment. Current Drug Metabolism, 2011, 12, 975-984.	1.2	19
89	Editorial [Hot Topic: Biomarkers of Chemotherapeutics Efficacy and Toxicity in Colorectal Cancer (Guest Editor: Amalia Azzariti)]. Current Drug Metabolism, 2011, 12, 917-917.	1.2	0
90	The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy. Current Drug Metabolism, 2011, 12, 713-721.	1.2	17

#	Article	IF	Citations
91	Pharmacokinetic and Metabolism Determinants of Fluoropyrimidines and Oxaliplatin Activity in Treatment of Colorectal Patients. Current Drug Metabolism, 2011, 12, 918-931.	1.2	11
92	MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment. European Journal of Pharmacology, 2011, 670, 74-84.	3.5	10
93	Kinase activation profile associated with TGF-Î²-dependent migration of HCC cells: a preclinical study. Cancer Chemotherapy and Pharmacology, 2011, 68, 79-86.	2.3	42
94	The clinical development of inhibitors of poly(ADP-ribose) polymerase. Annals of Oncology, 2011, 22, i53-i59.	1.2	42
95	EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Frontiers in Bioscience - Landmark, 2011, 16, 1962.	3.0	42
96	Nti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence. Frontiers in Bioscience - Landmark, 2011, 16, 1973.	3.0	7
97	Possibile role of vascular endothelial growth factor (VEGF) levels in immunodepleted plasma of metastatic colorectal cancer (mCRC) patients (pts) treated with a biweekly administration of capecitabine plus oxaliplatin (XELOX-2) plus bevacizumab: Preliminary results.. Journal of Clinical Oncology, 2011, 29, e14155-e14155.	1.6	1
98	Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemotherapy and Pharmacology, 2010, 65, 335-346.	2.3	45
99	Interaction of the Ïƒ₂ Receptor Ligand PB28 with the Human Nucleosome: Computational and Experimental Probes of Interaction with the H2A/H2B Dimer. ChemMedChem, 2010, 5, 268-273.	3.2	32
100	p53 as the main traffic controller of the cell signaling network. Frontiers in Bioscience - Landmark, 2010, 15, 1172.	3.0	12
101	Update on capecitabine alone and in combination regimens in colorectal cancer patients. Cancer Treatment Reviews, 2010, 36, S46-S55.	7.7	15
102	34 AZD1152 PLUS GEMCITABINE FOR PANCREAS CANCER TREATMENT: IN VITRO AND IN VIVO STUDY. Cancer Treatment Reviews, 2010, 36, S105.	7.7	0
103	46 IS BCRP EXPRESSION AND LOCALIZATION REGULATED BY EGFR PATHWAY IN NSCLC CELLS?. Cancer Treatment Reviews, 2010, 36, S108.	7.7	0
104	47 BIOLOGICAL CHARACTERIZATION OF MC70, AS POTENT INHIBITOR OF ABC TRANSPORTERS INVOLVED IN MULTIDRUG RESISTANCE. Cancer Treatment Reviews, 2010, 36, S109.	7.7	0
105	EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. Journal of Cancer Research and Clinical Oncology, 2009, 135, 771-782.	2.5	38
106	Intracellular Trafficking of MDR Transporters and Relevance of SNPs. Current Topics in Medicinal Chemistry, 2009, 9, 197-208.	2.1	25
107	Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 362-373.	3.0	78
108	4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators. Bioorganic and Medicinal Chemistry, 2008, 16, 3732-3743.	3.0	54

#	Article	IF	Citations
109	Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochemical Pharmacology, 2008, 75, 1035-1044.	4.4	47
110	EGFR and VEGFR as potential target for biological therapies in HCC cells. Cancer Letters, 2008, 262, 257-264.	7.2	48
111	Correction: Article on Phosphatidylinositol 3-Kinase in Breast Cancer. Clinical Cancer Research, 2008, 14, 1281-1281.	7.0	0
112	Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells. International Journal of Molecular Medicine, 2008, 21, 809-17.	4.0	3
113	High-Throughput Analysis of the Drug Mode of Action of PB28, MC18 and MC70, Three Cyclohexylpiperazine Derivative New Molecules. Lecture Notes in Computer Science, 2008, , 1085-1092.	1.3	0
114	Phosphatidylinositol 3-Kinase in Breast Cancer: Where from Here?. Clinical Cancer Research, 2007, 13, 5988-5990.	7.0	12
115	The NHERF1 PDZ2 Domain Regulates PKAâ€“RhoAâ€“p38-mediated NHE1 Activation and Invasion in Breast Tumor Cells. Molecular Biology of the Cell, 2007, 18, 1768-1780.	2.1	121
116	P27 Antiangiogenic activity of combining gefitinib and rapamycin in a panel of pancreas cancer cell lines. European Journal of Cancer, Supplement, 2007, 5, 31.	2.2	1
117	Laminin-5 stimulates hepatocellular carcinoma growth through a different function of Î±6Î²4 and Î±3Î²1 integrins. Hepatology, 2007, 46, 1801-1809.	7.3	63
118	Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate, 2007, 67, 782-789.	2.3	47
119	257 An inhibitor of VEGF(ZD6474) as a potential new drug for HCC: A preclinical study. Journal of Hepatology, 2006, 44, S102.	3.7	0
120	The complexity of targeting EGFR signalling in cancer: From expression to turnover. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1766, 120-139.	7.4	142
121	ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. Biochemical Pharmacology, 2006, 71, 479-485.	4.4	36
122	Cyclohexylpiperazine derivative PB28, a Ïƒ2 agonist and Ïƒ1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. Molecular Cancer Therapeutics, 2006, 5, 1807-1816.	4.1	108
123	Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressaâ„¢) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects. World Journal of Gastroenterology, 2006, 12, 5140.	3.3	25
124	Mitochondrial impairment induces excitotoxic death in cerebellar granule cells. International Journal of Molecular Medicine, 2004, 13, 873.	4.0	2
125	Laminin-5 offsets the efficacy of gefitinib (â€˜Iressaâ€™) in hepatocellular carcinoma cells. British Journal of Cancer, 2004, 91, 1964-1969.	6.4	50
126	The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressaâ„¢, ZD1839). Biochemical Pharmacology, 2004, 68, 135-144.	4.4	54

#	Article	IF	Citations
127	The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa?, ZD1839). Biochemical Pharmacology, 2004, 68, 135-135.	4.4	1
128	The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemotherapy and Pharmacology, 2003, 52, 442-448.	2.3	67
129	Characterization of sequence-dependent synergy between ZD1839 (â€˜Iressaâ€™) and oxaliplatin. Biochemical Pharmacology, 2003, 66, 551-563.	4.4	48
130	Combination of 5-Fluorouracil and Irinotecan on Modulation of Thymidylate Synthase and Topoisomerase I Expression and Cell Cycle Regulation in Human Colon Cancer LoVo Cells: Clinical Relevance. Clinical Colorectal Cancer, 2002, 2, 182-188.	2.3	10
131	Cytochrome c Is Released from Mitochondria in a Reactive Oxygen Species (ROS)-dependent Fashion and Can Operate as a ROS Scavenger and as a Respiratory Substrate in Cerebellar Neurons Undergoing Excitotoxic Death. Journal of Biological Chemistry, 2000, 275, 37159-37166.	3.4	187
132	Kinetic properties and thermal stabilities of mutant forms of mitochondrial aspartate aminotransferase. BBA - Proteins and Proteomics, 1998, 1386, 29-38.	2.1	8
133	Cumulative Effects of Mutations in Newly Synthesized Mitochondrial Aspartate Aminotransferase on Uptake into Mitochondria. Biochemical and Biophysical Research Communications, 1995, 214, 511-517.	2.1	1
134	Use of Protease Sensitivity to Probe the Conformations of Newly Synthesized Mutant Forms of Mitochondrial Aspartate Aminotransferase. Biochemical and Biophysical Research Communications, 1995, 215, 800-807.	2.1	0
135	The N-Terminal Region of Mature Mitochondrial Aspartate Aminotransferase Can Direct Cytosolic Dihydrofolate Reductase into Mitochondria in Vitro. Biochemical and Biophysical Research Communications, 1994, 201, 1059-1065.	2.1	4